Webinar: July 22, 2025 | 11:00AM EST In this webinar, you will learn: How to efficiently filter out non-specific binders early on to focus only on antibodies with true functional potential. Strategies to isolate highly specific anti-idiotype antibodies that avoid cross-reactivity with natural IgGs. The benefits of combining advanced enrichment techniques [...]
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
Written by: Genya Gorshtein, MSc Published: April 9, 2025 Contents Introduction What Is An Anti-Idiotypic Antibody? Applications of Anti-Idiotypic Antibodies in Drug Development Discovery and Generation of Anti-Idiotypic Antibodies Anti-Idiotype Antibody Discovery with Rapid Novor Introduction Anti-idiotypic antibodies are specialized antibodies that bind to [...]
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
Written by: Genya Gorshtein, MSc Published: December 12, 2024 Contents Introduction B Cells and Their Receptors Antibodies in Serum How Do You Discover Antibodies From Serum? Introduction While B cells play a crucial role in recognizing antigens and initiating immune responses, their differentiation into [...]
Written by: Genya Gorshtein, MSc Published: December 12, 2024 Contents Introduction BCR and Single B Cell Sequencing for Antibody Discovery Antibody Discovery through De Novo Sequencing of Serum Antibodies Proteogenomics: A Complimentary Approach Antibody Discovery With Rapid Novor Introduction B cell sequencing has long [...]
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
In this webinar, you will learn: How mAb irreproducibility could unknowingly impact your research outcomes Proven strategies to mitigate reproducibility risks when using research reagents The role of antibody sequencing in ensuring reproducibility with mAbs Rapid, cost-effective sequence confirmation for routine applications The next frontier: polyclonal antibody sequencing and recombinant pAbs [...]
Written by: Genya Gorshtein, MSc Published: August 26, 2024 Contents Introduction Advantages of Antibody Discovery In Diverse Species Unique Features of Antibodies from Diverse Hosts Antibody Discovery Platforms for Diverse Hosts Introduction The historical use of mice for monoclonal antibody generation has been driven [...]
Principal Scientist in Polyclonal Antibody Sequencing Dr. Thierry Le Bihan joined Rapid Novor as a Principal Scientist in 2018, tasked with leading a multidisciplinary team to develop a polyclonal antibody sequencing platform. Thierry brought extensive proteomics and mass spectrometry expertise from his previous roles as Director of Proteomics at The Campbell Family Institute [...]
This paper is now published in Nature Communications! Le Bihan, T., Nunez de Villavicencio Diaz, T., Reitzel, C. et al. De novo protein sequencing of antibodies for identification of neutralizing antibodies in human plasma post SARS-CoV-2 vaccination. Nat Commun 15, 8790 (2024). https://doi.org/10.1038/s41467-024-53105-8 In this webinar, you will: Explore how using a [...]
Written by: Vanessa Yoon Calvelo, PhD Published: June 6, 2023 Updated: July 7, 2024 Contents Introduction Early Discovery and Development of Therapeutic Antibodies Target Identification and Validation Antibody Discovery and Expression Lead Characterization and Selection Lead Engineering and Optimization Candidate Selection and Downstream Characterization Introduction [...]
Written by: Jenna Kerry, MSc Published: June 10, 2024 Contents Introduction Advantages of Recombinant Antibody Cocktails Recombinant Antibody Cocktail Formats Engineering Recombinant Antibody Cocktails Production of Recombinant Antibody Cocktails Recombinant Antibody Cocktail Applications Generate Antibody Cocktails with De Novo Antibody Sequencing Service Introduction Recombinant antibody [...]
Authors: Teresa Nunez, Amber Couzens, Jin Duan, Chelsea Reitzel, Rosalin Dubois, Lin Wu, Qixin Liu, Thierry Le Bihan, Marko Jović, Dominic Narang, Bin Ma Published: Nov 13, 2023 Abstract In this study, the challenge of accessing functional antibodies from the circulating antibody repertoire was addressed using Rapid Novor's antibody [...]
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
In this webinar, you will learn: About the challenges commonly encountered in antibody discovery campaigns, including non-functional antibodies, limited diversity, developability issues, and immunogenicity. How to de-risk antibody discovery campaigns, while balancing speed and spend Discover how a proteomics and mass spectrometry-based approach to antibody discovery, utilizing REpAb polyclonal sequencing, presents [...]
Written by: Genya Gorshtein, MSc Published: May 9, 2023 Contents Introduction Hybridoma Instability Leads to mAb Irreproducibility Batch-to-Batch Variation in Polyclonal Antibodies Antibody Sequencing and Recombinant Expression Ensures Reproducible Antibody Reagents Generating Reproducible Reagents with Rapid Novor Introduction Antibodies (Abs) are indispensable tools in [...]
In this webinar, you will learn: IVD and immunoassays, supply chain risk management considerations How monoclonal and polyclonal antibody sequencing works, requirements Effective production, validation, and scale-up of recombinant antibody reagents Characterization of mAbs for assay design Abstract Polyclonal antibodies (pAbs) are well known for their robustness and [...]
In this webinar, you will learn: How Rapid Novor’s de novo polyclonal sequencing platform REpAb® can accelerate any nanobody development pipeline How SPR and HDX-MS integrate into an antibody discovery and development workflow How to choose optimal lead candidates with SPR and HDX-MS How epitopes can be characterized using SPR and HDX-MS [...]
The great debate on the use of in vivo versus in vitro sources and strategies for antibody discovery and generation continues to thrive among antibody research groups. On one side of the debate is the argument for non-animal-derived antibodies due to the technical advancements of current in vitro technologies, and the moral obligation to reduce animal usage. On the other side of the debate is the counterargument for animal-derived antibodies due to their better performance in affinity, specificity, and reduced immunogenicity risk.
In this SPR webinar, you will learn: How SPR works and its unique advantages for kinetic analysis of antibody-antigen interactions Applications of SPR in antibody discovery Functionality of SPR in antibody characterization Abstract Due to their ability to bind biomolecules specifically and tightly, antibodies are highly sought [...]
Written by Genya Gorshtein, MSc Updated: January 27, 2023 (Published: August 31, 2022) Contents How is Antibody Diversity Generated? Which Steps Contribute to the Generation of Antibody Diversity? Antibody Loci and V(D)J Recombination Somatic Hypermutation Class Switch Recombination De Novo Proteomic Sequencing of Antibodies How is Antibody [...]
Written by: Genya Gorshtein, MSc Published: August 18, 2022 Contents Introduction How are Polyclonal Antibodies Produced? Applications of Polyclonal Antibodies Challenges of Polyclonal Antibodies De Novo Polyclonal Antibody Sequencing Introduction Polyclonal antibodies (pAbs) are a heterogeneous mix of antibodies derived from B cells in the [...]
Written by Genya Gorshtein, MSc August 10, 2022 Contents General Structure of Antibodies Fab and Fc Fragments Hinge Region CDR and FR Regions Antibody Structure Analysis Services General Structure of Antibodies Antibodies or immunoglobulins (Ig) maintain a common quaternary structure consisting of two identical heavy chains (HCs) and [...]
Written by: Vanessa Yoon Calvelo, PhD Published: July 11, 2022 Contents What is Gene Therapy? What are Adeno-Associated Viruses? Engineering of AAVs for Gene Therapy Engineering AAVs for Improved Transduction Engineering AAVs for Improved Immunogenicity De Novo Protein Sequencing Applications in AAV Characterization and Development What is Gene [...]
Written by: Vanessa Yoon Calvelo, PhD Published: June 13, 2022 Contents What is CAR-T Cell Therapy? CAR Structure and Function CAR-T Cell Development Engineering Strategies for CAR-T Cells De Novo Protein Sequencing Applications in CAR-T Cell Development What is CAR-T Cell Therapy? The infusion of T cells [...]
The most straightforward solution would be to determine sequences of the dominating antibody forms in a polyclonal mixture to enable recombinant antibody generation and ensure reproducibility. This was recently made possible by the development of polyclonal antibody sequencing technology, which will be reviewed in this article.
Circulating in blood is a multitude of biologically important antibodies. These pools of polyclonal antibodies (pAb) are invaluable sources for drug discovery against various diseases, and for the development of robust immunoreagents for diagnostics, and research.
Written by: Yuning Wang, PhD Updated: January 18, 2023 (Published: January 21, 2022) Contents Discovery of Camelid Antibodies What are Camelid Antibodies? Structure of Camelid Antibodies and Nanobodies Advantages of Camelid Antibodies and Nanobodies Camelid Antibodies and Nanobodies for Therapeutic and Research Applications How are Camelid Antibodies [...]
Recombinant antibodies are artificially synthesized antibodies. Recombinant antibodies are generated from expression systems (e.g., E.coli, yeast, mammalian cell lines) via transfection with two separate plasmids encoding the amino acid sequences for the light and heavy chains, respectively. In order to recombinantly produce mAbs, the amino acid sequence of the light and heavy chains must be known. There are many ways to obtain the sequence of an antibody.
Over the past several years Rapid Novor has been developing the world's best antibody protein sequencing platform, with over 2700 monoclonal antibodies and proteins sequenced. In 2020, they unveiled their most advanced technology to date- REpAb® polyclonal antibody sequencing. The platform combines the world's best protein sequencing technology and NGS to comprehensively mine the antigen specific antibody repertoire present in rabbit and human patient samples. By leveraging the platform, teams can build robust antibody assays and therapeutic leads derived from patient's blood.
Since 2006, the One Health Initiative (OHI)’s goal has been to demonstrate the inextricable link between humans, animals, and the environment. Certainly, the current global pandemic is a great testament to the ties between climate change, humans, and animals that OHI has been working to highlight. The rise of other zoonotic diseases (e.g., Hendra, and Nipah viruses) not only directly affect humans through disease transmission but may also result in deep impacts to the food supply
Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.
The transition from polyclonal antibody drugs to a more targeted monoclonal approach was made possible through a series of scientific and technological advancements; the most notable of which is the hybridoma technique developed by Köhler and Milstein, which allowed the generation of pure antibodies at scale.
DNA sequencing is the process of determining the precise order of four nucleotides bases—adenine (A), guanine (G), cytosine (C), and thymine (T)—that make up the DNA molecule. From Sanger sequencing to next-generation sequencing (NGS), DNA sequencing’s accessibility and ease of use make it one of the most widely used technologies in life sciences.
Protein mass spectrometry refers to the use of mass spectrometry in studying and characterizing proteins, including their quantification, profiling, interaction mapping, and identification of their post-translational modifications. Protein mass spectrometry may also be referred to as mass spectrometry-based proteomics. Mass spectrometry-based proteomics comprises three approaches: top-down, middle-down, and bottom-up proteomics.
The protein sequence is key to understanding the function of a protein target and is critical to therapeutic and diagnostic development. This is particularly important for antibodies whose code diversity and glycosylation impact both function, and stability.
Antibody sequences are critical for antibody engineering and protein characterization in therapeutic development. For antibody reagent users, knowing the sequences allows them to perform sequence analysis/alignment to identify binding and cross-reactivity so they can conduct rational experiment design.
Over the past 5 years Rapid Novor has perfected monoclonal antibody sequencing, and is now sequencing mAbs from polyclonal mixtures using REpAb®. After successfully launching their proteogenomics based sequencing technology to deconvolute the immune response, the team has further evolved the technology and has derived the most abundant mAb sequences directly from rabbit blood using only proteomics. The talk will surround the development, progress and use cases for REpAb®.
Over the past several years Rapid Novor has been developing the world’s best antibody protein sequencing platform, sequencing over 2700 monoclonal antibodies and proteins. In 2020, they unveiled their most advanced technology to date - REpAb® polyclonal antibody sequencing. The platform combines the world’s best protein sequencing technology and NGS to comprehensively mine the antigen-specific antibody repertoire present in rabbit and human patient samples. By leveraging the platform, teams can build robust antibody assays and therapeutic leads derived from patients’ blood.
When it comes to polyclonal antibodies, how they are discovered can be just as important as how they are reproduced. In our talk originally presented at Antibody Engineering & Therapeutics Digital 2021, we highlighted the latest technology that’s capable of capturing the most abundant and high-affinity monoclonal antibodies directly from a poly mixture.
Recombinant Monoclonal Antibodies (rAbs) are highly reproducible, customizable and pure alternatives to the traditional antibodies produced by hybridomas. Get the antibody protein sequence, either by DNA sequencing or the de novo protein sequencing technology, you can rest assured that you can have the exact antibody made recombinantly anytime in the future.